European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to- severe atopic dermatitis (ADTrust): Study protocol - Augustin M; Bewley A; Bruggen MC; De Bruin-Weller MS; Ezzedine K; Ferrucci SM; Gkalpakiotis S; Herranz P; Johansson EK; Kampe T; Lapeere H; Legat FJ; et al. (Bmj Open, 2025)